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The 5,12-dihydroxy metabolite of arachidonic acid, 
leukotriene B., is a highly potent neutrophil chern oat-
tractant. In v iew of the characteristic epidermal neutro-
phil infiltrate in psoriasis , the presence of leukotriene 
B. in samples from untreated les ional and uninvolved 
skin has been sought. Chambers were fixed to abraded 
skin and filled with phosphate-buffered saline (PBS). 
After 35 min , the fluid was removed, and acidic lipids 
were extracted and subjected to high-performance liq-
uid chromatography (HPLC) . Extracts were purified by 
both straig ht- and reversed-phase HPLC, and assay of 
evapo rated fractions b y an agarose microdroplet che-
mokinesis technique indicated the presence of leuko-
triene B.,-Iike material. No significant leukotriene B.,-
like activity was found in samples from uninvolved skin. 
Subsequent experime nts using a modification of the in-
itial ski n chamber method indicated that leukotriene B., 
was being released from deeper laye r s of lesional skin 
and not only from superficial scale. Monohydroxy-ei-
cosatet r aenoic acid-like activity was also seen in le -
sional samples as determined by s traight-phase HPLC 
and chemokinesis assay. These findings and the pro-
infla mmato r y properties of these compounds in human 
skin suggest that they may playa role in the pathogen-
esis of the psoriatic neutrophil infiltrate. 
Arac hido ni c acid can be metabo li zed by lipoxygen ase e n -
zy mes to produce m o no- a nd dihydroxy-e icosatetraenoic acids 
a mo ng othe r compounds. In 1975 it. was reported that 12(S)-
hydroxy-i1 ,8,l4 -cis-lO-tra.n.s-e icosatetr ae noic ac id (12-HETE) 
was che motactic fo r neu t rop hil s at hi gh co nce n t rations [1]. 
S ince th is findin g, it has bee n s hown that other mono-HETE 
compounds have c he motactic a nd c hemokinetic as we ll a s othe r 
e ffects o n le ukocytes in vitro [2- 4 ]. M o re rece nt ly leukotrie ne 
B., [5( S) ,12( R ) -dihydroxy-6,l4-cis-8, lO -tran.s-eicosatetraenoic 
acid , L'fR,J has been cha ract.eri zed [5,6] a nd found to be 
co ns ide rably m o re poten t as a modulator o f leukocyte [unction 
t han t he mono-HETE compounds. Indeed, it has been found 
( 0 be o ne of t.he m ost. potent c he m otactic a nd c hemokinetic 
compounds known fo r leukocytes in v itro [7,8], with a pote ncy 
si mila r ( 0 t hat o f t he mino r fragm e n t 0 (' t he fi ft h compo nent o f 
co mplem e nt. C!)a 19]. 
It is probabl e that t he prese nce of le uk otactic factors in t he 
epide rmi s is re leva n t to t he pat hoge nes is o f the in t raepide rm a l 
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Abb reviat ions: 
CC-MS: g<ls chromatography-mass spectrometry 
12- H E:TE: 12(8) -hyd roxy -5,8, 14 -cis - ! O-trans-eicosatetrae noic 
acid 
H PLC: high -performance liquid chromatography 
L TB.,: leuk otrie lle B., 
PBS: phosphate-buffered sa lin e 
n eu trop hil infi ltrate in t he s kin lesio ns of p soriasis . I t h as been 
reported brie !1y that acidic lipid ex tracts of chamber !1uid from 
ab raded lesiona l psoriatic skin contain s ignifican t ch e m okinetic 
activ ity when compared wi t h samples fro m t h e uninvo lved skin 
o f psori at ics or from t he s k in o f norm al volunteers [10] . Details 
of t he furt h er a n a lys is of s uc h extracts by a combinat io n of 
high -pe rfo rma nce liquid chromatography (HPLC) a nd a n assay 
o f leukocyte chemokinetic activi ty a re now presented. 
MATERIALS AND METHODS 
Dextran 70 injection B.P. (6% w/v in 0.9% sodium chloride), organic 
solvents, Eagle's minimal essential medium, 1.0 M Hepes buffer, aga-
rose-indub iose. hepa rin injection B.P. (5000 units/m\), L TB." 12-
HETE, and 5-HETE were obta ined as recently desc ribed (11). S ilicic 
acid (SilicAR CC4) was obt.a ined from Mallinckrodt, St. Louis, Mis-
souri , and all other reagents from B.D.H ., Poole, Uni ted Kingdom. 
Phosphate- buffered saline, pH 7.3, conta ined 0.04 M sodium phosphate 
a nd 0.1 54 M sodium chloride and was sterili zed by autoclaving. 
All voluntee rs gave informed consent, a nd tbe project had t he 
approval of t.he Institute Et hical Com mittee. In preliminary studies, 
un treated pl aques of chronic pso rias is and clinically normal skin of t he 
sa me patients were abraded with a scalpel blade over an a rea of 2 cm2 
to t he level at which a glistening surface with minimal punctate 
bleeding was obtained. Histologic examination of skin biopsies of 
abraded a reas revealed t hat in some suprapap illa ry areas, fu ll -thickness 
epidermal loss had occurred, but that the major portion of the epidermal 
rete ridges had bee n prese rved. Cylindrical glass cha mbers of 6 cm' 
cross-sectional area were fix ~d wi th adh esive tape to the abraded sites 
and fill ed with 1 ml sterile PBS. The chamber f1uid was removed after 
35 min a nd cent rifuged at 350 g for 10 min . Any deposit was subjected 
to total leukocyte coun ts by dilution with gentian violet in 2% acetic 
ac id a nd coun t in g in an improved Neubauer cou nti ng cha mber. 
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Chamber f1uid supernatants (usually 1 ml) were acidified by addition 
of an equal volume of 0.1 M sodium acet.ate buffer, pH 3.5, a nd lipids 
ext.racted by part it ioning twice wit h 2 volumes of ethyl acetate. The 
et hyl acetate phases were evaporated and desiccated under vacuum. 
Chamber f1u id extracts from lesional psoriatic skin were purified by 
two sepa rate chromatographic systems. In one, a stra ight-phase hi gh-
performance liquid chromatography (HPLC) syste m with a Spherisorb 
S5W silica column (25 cm X 4.9 mm 10) a nd solvent containing 
hexa ne:propa n-2-01:methanol:acetic acid (93:5:2:0.1 by volume) at a 
f10w rate of 1 ml/ min was used. One-minute eff1uent fraction s were 
collected, evaporated, and t hen prepared for chemokinesis assay by 
dissolving each fraction in 300 II I Eagle's minimal essent ial medium 
(MEM) bu ffered to pH 7.4 with 20 mM Hepes buffer. In t he second 
system, ethyl acetate extracts of chamber f1uid were purified on 0.3-g 
silicic acid columns. Nonpolar material was removed by elu tion wi th 
1() ml hexane:diethyl ether (80:20 by volume) a nd more pola r material 
with 10 ml ethyl ace tate I f,]. The evaporated ethyl acetate phase was 
subjected to reversed-phase HPLC lIsing a Spherisorb S50DS co lumn 
(2!) em x 4.9 mm 10) eluted with methano l:watc r:acetic acid (72:28:0.01 
hy volume) at 1 ml/ min . One- minute efflu ent fractions were collected, 
evapo rated, a nd prepa red for bioassRY :1S desc ribed above. 
Using the cha mber method described above, I -ml samples were 
obt a ined from t he les ional a nd clinically uninvolved skin of 11 patients 
with un t reated chronic plaque psoriasis. Acidic lipid extract.s were 
obta in ed as described, and the evaporated ethyl acetate residues were 
subject.ed to HPLC on t.he desc ribed silica column elu ted with hex-
ane:p ropa n-2-ol:methano l:acetic ac id (88:7:5:0. 1 by volume) at 1 ml / 
min. Fractions with the same retention t ime as st.andard leukotriene 
B.\ were collected, evaporated, a nd assayed for chemoki netic activity as 
described below. 
In the skin cha mber met.hod described above, t he cross-sect ional 
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a rea of t he chamber was greater t han the area of abraded skin , indical-
ing that in lesional pso riatic skin , chamber fluid was in direcl cont act 
wit,h unabraded psoriatic sca le. In view of the findin g 11 1J I hal psoriatic 
scale contains chemokinetica lly aCl ive amount s of acidic lipid material, 
further ex perim ent s were ca rried out to determine whether the elution 
of biologically act ive material directly from intac t surface scale could 
expla in the chemok inet ic activity found in the chamber fluids obta ined 
as desc ri bed above. In these experiments , lesional and clinically unin -
volved pso riatic skin was abraded over a circular a rea of approximately 
3.5 cm2. Cy lindri ca l plas tic chambers of 3.fi cm2 cross-sectional a rea 
were fixed (" 0 I he abraded sites with cyanoacrylate glue slIch thaI only 
abraded skin was contained within t he chamber. Sterile PBS (1 ml ) 
was added LO eac h chamber and removed and disca rded after 2 min , 
t hus servin g as a wash. A furth er 1 ml of P BS was added LO each 
chamber and was left for 30 min . Eac h sample was then removed, and 
acidic lipid extracts were obta ined as described above. The evaporated 
ethyl acetate residues were subjected to straight-phase HPLC using the 
described Spherisorb S.')W colu mn eluted with hexane:propan-2-
o l: methanol:acetic acid (88:7:5:0.1 by vo lume) at 1 ml/ min . Initia lly. 
samples from lesional skin were chromatographed in t his system, and 
I- ml effluent fractions we re collected, evaporated, and assayed for 
chemokinetic ac t ivity. Therea fter, sa mples from lesional and unin -
vo lved skin of 7 patients were extracted and purified by t his H PLC 
method. Frac tions corresponding with the elution time of standard 
L T B" were co llected and assayed for chemokinetic activity. 
Chemokinet.ic activity was assayed using an agarose microdroplet 
tec hnique 11 2], as recently described I j] J. Chemokineti c ac ti vity was 
expressed as t he distance moved by leukocytes from the agarose mi -
crodroplet less spontaneous random movement in t he presence of M EM 
a lone (see Figs 1- 3). When chemokin etic activity was measured in 
1-1 PLC fractions wi th t he identica l retent ion t ime to L TB." activit.y was 
assayed direct ly aga inst that of standard L TB", and results were 
expressed as picograms of L T B., equiva lents per milliliter of chamber 
fluid (T able J). 
RESU LTS 
In prelimina ry experime nts, fe w or no le ukocytes we re found 
in depos its a fte r ce nt r ifu gat ion o f chamber l1uids, and the re 
was no corre la ti on between ac idic lipid c he mokin etic activity 
in cha mbe r l1uids a nd the numbe r of leuk ocytes, when prese n t . 
E t hy l a ce ta te e xtrac ts obtained by using t he fir t chamber 
m ethod desc ribed a bove we re purified by two separate chro-
m a t ographic syste ms. Figure 1 s hows th e c he mo kinetic activity 
fo und in fractions a fte r stra ight-phase HPLC of a s ingle-
c ha mber fluid ex tract from invo lved s kin a nd de monstra tes two 
m ajo r peaks . The first major peak o f chem okinetica lly act ive 
m ateri a l (frac ti ons 7- 9) coeluted with s ta nda rd 5- H ETE a nd 
12-HETE (these monohydroxy metabolites of a rac hidoni c acid 
a re not s ignifi ca n t ly sepa ra ted from eac h othe r in this HPLC 
system). The second major peak of chem okinetica lly ac tive 
m ate ria l (fractio ns 30-3 1) eluted with a n ide n t ical re te ntio n 
t ime to t hat of standard L TB.,. Figu re 2 s hows typica l c he mo-
kinetic activi ty in fractions a fte r reversed -phase HPLC o f a 
s ingle lesiona l cha mbe r fluid extract purifi ed by s ilic ic ac id 
chrom a togra phy. M ate ria l causing a major peak o f c he moki -
neti c activity (fractions 10- 11) a ga in coeluted wi t h au t he ntic 
LTB." a lt hough in t.hese chrom atogra ms m ono- HETE- like ac-
t ivity was not see n , as shown in Fig 2. 
TABLE J. M easu rement of LTB, equ ivalents ill chamber fluid 
Sa mple source 
Uninvolved skin 
Involved skin 
I.'I'B., equiva lellLs 
(Iirst chamher meLhod )" 
No. of 
chambers 
11 
11 
pg/ml 
N. D. 
lO!) ± 3 1" 
I .TH. equi va lent.s 
(second chamber 
method)" 
o. of 
chambers 
G 
7 
pg/ ml 
N. D.' 
68 ± j !)d 
a Abraded a rea of 2 cm" was covered by 6-cm2 chamber. 
b Abraded area of 3.5 cm2 was covered by 3.5-cm2 cha mber. 
< N.D. = not detectable. Six of seve n sa mples tes ted contained no 
detectable activity, the remaining sample containing 4.2 pg L T B., 
equivalents per milliliter. 
" Mea n ± SEM. 
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FIG 1. Representa tive chemok inetic activity in straight -phase 
HPLC fractions of a s ingle lesional chamber fluid ex t.rac t. The sa mple 
was obtained from involved psoriatic skin by using t.he first chamber 
method, in which chamber f1uid was in contac t wi th both abraded and 
intact les ional surfaces. Activity is expressed as the distance moved by 
leukocytes from the aga rose droplet less spontaneous random move-
ment in t he presence of MEM alone. The mean of duplicate obse rva-
tions is given for each frac tion. Elu t ion times of st.andard 12- HETE 
(A) , 5- HETE ( B ) , and LTB, (C) are shown . 
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FJ(: 2. Represent.at ive chemokinetic act ivit y In reversed-phase 
HPLC frac tions of a single les ional chamber fluid extract. The sample 
was obta ined from involved psoriatic skin by using t.he first chamber 
method. Chemokinetic ac tivity and elu tion times of standa rds are 
expressed as in Fig I.. 
Fluid was obtained from les iona l a nd uninvolved s kin of 11 
psoriatic pat ients using t he first cha mbe r method a nd was 
purified by stra ight-phase HPLC as desc ribed. S ignifica n t 
LTB., -like chemokinetic materia l was found in samples from 
lesio na l s kin , whe reas cha mbe r l1uid from uninvolved s kin 
co n ta ined no detecta ble L TB., activi ty (Table I). Limit.s of 
detect.ion for LTB., in the chem okin es is assay a re 3- 9 pg/ ml o f 
cha mber fluid sample . 
In t he second s kin cha mber method , only t he abraded s kin 
surface was in con tact wi t h cha mber fluid , and a prelimina ry 
wash was ca rried ou t . S tra ight-phase H P L C of ac idic lipid 
ext racts o f lesional chamber fluid obta ined in t.hi s way was 
done as described. Assay o f eva pora t.ed 1-ml efflu en t fractions 
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Flc; 2. Repre,entative chemok inet.i c acti vity in straight-pha,e 
H PLe fractio ns of a single lesional chamber fluid extract. The sample 
was obta incd from in vo lved psoriatic skin by using the second chamber 
method, in which the chamber tluid was in cont act only with abraded, 
washed lesional skin . Chemokinctic activi ty and elu tion times of stand-
ards are expressed as in Fig 1. 
agai n showed two majo r pea ks of chemokinetic materia l, with 
retenti on c h ~lJ"ac(,e ri st i cs of the mono-H ETEs (fractions 5- 6) 
a nd L 1'8., (fraction 14 ) (Fig 3). When such chambe r (luid was 
obta ined from the lesiona l and uninvolved skin of 7 psoriati c 
volunteers a nd purifi ed by stra ight-p hase HPLC as described, 
lesiona l sa mples aga in conta ined significan t ly greater L TB., -
li ke ac tivity than samples from uninvolved skin, wi t h only 1 of 
7 sa mples from unin volved skin con ta in ing detectable activity 
(Table J). 
DlSCUSS ION 
Chemok inesis assay of chamber fluid purified by straight-
phase H PLC suggests t hat t he acidic lipid chemokinetic mate-
ria l in . a mples from lesiona l psoria t ic s kin [10] is due to a 
mixture of mono-HETE- and LTB,,- like materi al (Fig 1). As-
says of lesiona l chamber fl u id purified by s ilicic acid chroma-
tography and reversed -phase HPLC supported the find ing of 
an L TE,- li ke substance, a lt hough with t hi s purifica tion system 
mono-HETE-li ke act ivity was not seen (Fig 2). This appea red 
to be due to loss of mono-HETE- like mate rial durin g t he 
preparative s ilicic ac id step, which was necessa ry to prevent 
reversed-phase co lumn dete ri oration . Semiquantitative che-
mokinetic assay of HPLC- purifi ed extracts (Table n showed 
t hat samples from lesiona l skin contained LTI3,,- like activity, 
but t hose from uninvolved skin did not. These assays were 
carri ed out wit hout the use of in te rn a l standa rds, a nd fin a l 
amounts a re t herefore not corrected for recovery. Subsequent 
experiments usi ng chamber fluid in contact with totally 
abraded, washed skin (Fig :3) confirmed that biologically active 
amounts of t hese compound f; were released from t he deepe r, 
viable layers a nd could not be entirely accounted for by release 
from superfi cia l psoriatic scale. Sem iquantitative chemokin etic 
ana lys is of H PLC-purified samples obtained by the second 
cha mber method aga in showed signi fica nt amounts of an LTR, -
like compound in lesiona l samples but not in those from un in -
vo lved skin. U nequivoca l identi fi ca tion of several mono-HETE 
compounds in extracts of scale a nd chambe r f1uid from les iona l 
pso ri at ic skin by gas chromatography- mass spectrometry (GC-
MS) has recently bee n reported, but semiquan titative GC-MS 
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assays indicated t hat only 12-HETE was p resent in lesiona l 
extracts in potentia lly biologially active a moun ts [11), confirm -
ing a prev ious report [13] of la rge amounts of 12-HETE in 
]esion al psoriatic skin. 
These findin gs support t he possibility that a leukotriene 13.-
li ke substance and 12-HETE may p laya role in the pathogen-
esis of t he psoriatic neutrop hil inlil trate. The cells of ori gin of 
L TB,, -]ike materi a l in lesiona l psoria tic skin remain to be 
determined. Human polymorphonuclea r leuk ocytes release sub-
stan t ia l amounts of LTR, in vitro [5 ], a nd it is t herefore 
possible that L TR, is released from neutrop hil s afte r their 
a rriva l in lesiona l sk in a nd t hat it plays a role more in t he 
ma in tena nce rathe r t.han in initiation of the infil t rate. Whether 
L TB" is relevant to the ini tia l rec rui t men t of neut rophils in 
t he pso ri atic lesion depends on the ability of skin ce ll s to 
syn thes ise L 1'13". This is present ly under study. GC-MS exper-
iments to determine t he exact structure of the LTB., -like sub-
stance a re a lso continuin g. The levels of mate ria l obtainable 
were too low to a ll ow ident ification by ultraviolet abso rba nce 
characte ristic' or by ul t ravio let abso rbance monitoring of 
HPLC efi1u ents. 
Intraderma l injection of 50- 500 ng LTR, [14,15 ] a nd intra-
dermal in fus ion of microgram quanti t ies of 12-HETE [16] in 
human vo lun teers induce a local derma l infil trate of leukocytes 
rich in neut rophil s, especially in t he case of L 1'13" . Topical 
application of 5- 500 ng L 1'13" to the skin of huma n subjects 
produces a pers istent inflammatory reaction with t he fo rm ation 
of in t raep idermalneutrophil microabscesses [17J. These in vivo 
pro- infl ammatory properties in human skin support furth er t he 
ro le of t hese compounds in t he pathogenesis of the neut rophil 
infil t rate of pso riasis . The importance of these compounds in 
relation to other chemotactic substances, such as the C5a- like 
mate ria l ident ified in psoriatic scale [18], in the induction of 
t he pso ri atic neut rophil infil trate remains to be dete rmin ed . If 
neutrophil infil t ration is a key event in the pathogenesis of 
psoriasis [19], t hen arac hidonate lipoxyge nase inhibi to rs could 
possess t herapeut ic activity in psoriasis . Whether such inhibi-
tory activi ty form s the basis of t he t herapeutic effect of benox-
aprofen in psoriasis [20] iJ as yet unknown. 
T he aut.hors are grateful to S. Mist.ry and J. Isaacs for expert 
technical ass istance. 
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